Armata Pharmaceuticals (NYSE:ARMP) said its inhaled bacterial infection drug for lung disorder was well-tolerated with a treatment emergent adverse event (TEAE) profile similar to placebo in a phase ...
The average one-year price target for Armata Pharmaceuticals (NYSEAM:ARMP) has been revised to $17.85 / share. This is an ...
Armata Pharmaceuticals has posted early validation of its phage platform. The phase 1b/2a trial linked a bacteriophage cocktail to improved outcomes in patients with bacteria in their blood, opening ...
Armata Pharmaceuticals, Inc. (NYSE American: ARMP) ("Armata" or the "Company"), a clinical-stage biotechnology company focused on the development of high-purity, pathogen-specific bacteriophage ...
LOS ANGELES, March 12, 2025 /PRNewswire/ -- Armata Pharmaceuticals, Inc. (NYSE American: ARMP) ("Armata" or the "Company"), a clinical-stage biotechnology company focused on the development of ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results